163 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00001 | Citropin modified peptide-3 | GLFAVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 6 M |
| dbacp00002 | Citropin modified peptide-3 | GLFAVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 6 M |
| dbacp00003 | Citropin modified peptide-3 | GLFAVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Colon tumor cell line | Colon cancer | IC50 : 6 M |
| dbacp00004 | Citropin modified peptide-3 | GLFAVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Brain tumor cell line | Brain tumor | IC50 : 6 M |
| dbacp00005 | Citropin modified peptide-3 | GLFAVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Skin tumor cell line | Skin cancer | IC50 : 6 M |
| dbacp00006 | Citropin modified peptide-3 | GLFAVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 6 M |
| dbacp00007 | Citropin modified peptide-3 | GLFAVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : 1 µM |
| dbacp00008 | Citropin modified peptide-3 | GLFAVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 6 M |
| dbacp00009 | Citropin modified peptide-3 | GLFAVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 6 M |
| dbacp00010 | Citropin modified peptide-5 | GLFDVIKAVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00011 | Citropin modified peptide-5 | GLFDVIKAVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00012 | Citropin modified peptide-5 | GLFDVIKAVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Colon tumor cell line | Colon cancer | IC50 : 5 M |
| dbacp00013 | Citropin modified peptide-5 | GLFDVIKAVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Brain tumor cell line | Brain tumor | IC50 : 5 M |
| dbacp00014 | Citropin modified peptide-5 | GLFDVIKAVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Skin tumor cell line | Skin cancer | IC50 : 100 µM |
| dbacp00015 | Citropin modified peptide-5 | GLFDVIKAVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00016 | Citropin modified peptide-5 | GLFDVIKAVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : 100 µM |
| dbacp00017 | Citropin modified peptide-5 | GLFDVIKAVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00018 | Citropin modified peptide-5 | GLFDVIKAVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00019 | Citropin modified peptide-7 | GLFDVIKKVAAVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00020 | Citropin modified peptide-7 | GLFDVIKKVAAVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00021 | Citropin modified peptide-7 | GLFDVIKKVAAVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Colon tumor cell line | Colon cancer | IC50 : 5 M |
| dbacp00022 | Citropin modified peptide-7 | GLFDVIKKVAAVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Brain tumor cell line | Brain tumor | IC50 : 5 M |
| dbacp00023 | Citropin modified peptide-7 | GLFDVIKKVAAVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Skin tumor cell line | Skin cancer | IC50 : 5 M |
| dbacp00024 | Citropin modified peptide-7 | GLFDVIKKVAAVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00025 | Citropin modified peptide-7 | GLFDVIKKVAAVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : 5 M |
| dbacp00026 | Citropin modified peptide-7 | GLFDVIKKVAAVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00027 | Citropin modified peptide-7 | GLFDVIKKVAAVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00098 | Citropin modified peptide-11 | GLFDVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00099 | Citropin modified peptide-11 | GLFDVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00100 | Citropin modified peptide-11 | GLFDVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Colon tumor cell line | Colon cancer | IC50 : 5 M |
| dbacp00101 | Citropin modified peptide-11 | GLFDVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Brain tumor cell line | Brain tumor | IC50 : 5 M |
| dbacp00102 | Citropin modified peptide-11 | GLFDVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Skin tumor cell line | Skin cancer | IC50 : 5 M |
| dbacp00103 | Citropin modified peptide-11 | GLFDVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00104 | Citropin modified peptide-11 | GLFDVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : 5 M |
| dbacp00105 | Citropin modified peptide-11 | GLFDVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00106 | Citropin modified peptide-11 | GLFDVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00107 | Citropin modified peptide-13 | GLFDVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00108 | Citropin modified peptide-13 | GLFDVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00109 | Citropin modified peptide-13 | GLFDVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Colon tumor cell line | Colon cancer | IC50 : 5 M |
| dbacp00110 | Citropin modified peptide-13 | GLFDVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Brain tumor cell line | Brain tumor | IC50 : 5 M |
| dbacp00111 | Citropin modified peptide-13 | GLFDVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Skin tumor cell line | Skin cancer | IC50 : 5 M |
| dbacp00112 | Citropin modified peptide-13 | GLFDVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00113 | Citropin modified peptide-13 | GLFDVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : 5 M |
| dbacp00114 | Citropin modified peptide-13 | GLFDVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00115 | Citropin modified peptide-13 | GLFDVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00116 | Citropin modified peptide-14 | GLFDVIAKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00117 | Citropin modified peptide-14 | GLFDVIAKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00118 | Citropin modified peptide-14 | GLFDVIAKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Colon tumor cell line | Colon cancer | IC50 : 5 M |
| dbacp00119 | Citropin modified peptide-14 | GLFDVIAKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Brain tumor cell line | Brain tumor | IC50 : 5 M |
| dbacp00120 | Citropin modified peptide-14 | GLFDVIAKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Skin tumor cell line | Skin cancer | IC50 : 5 M |
| dbacp00121 | Citropin modified peptide-14 | GLFDVIAKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00122 | Citropin modified peptide-14 | GLFDVIAKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : 5 M |
| dbacp00123 | Citropin modified peptide-14 | GLFDVIAKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00124 | Citropin modified peptide-14 | GLFDVIAKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00150 | Citropin modified peptide-15 | GLFAVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00151 | Citropin modified peptide-15 | GLFAVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00152 | Citropin modified peptide-15 | GLFAVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Colon tumor cell line | Colon cancer | IC50 : 5 M |
| dbacp00153 | Citropin modified peptide-15 | GLFAVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Brain tumor cell line | Brain tumor | IC50 : 5 M |
| dbacp00154 | Citropin modified peptide-15 | GLFAVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Skin tumor cell line | Skin cancer | IC50 : 5 M |
| dbacp00155 | Citropin modified peptide-15 | GLFAVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00156 | Citropin modified peptide-15 | GLFAVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : 5 M |
| dbacp00157 | Citropin modified peptide-15 | GLFAVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00158 | Citropin modified peptide-15 | GLFAVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00183 | Citropin modified peptide-16 | GLFAVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00184 | Citropin modified peptide-16 | GLFAVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00185 | Citropin modified peptide-16 | GLFAVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Colon tumor cell line | Colon cancer | IC50 : 5 M |
| dbacp00186 | Citropin modified peptide-16 | GLFAVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Brain tumor cell line | Brain tumor | IC50 : 5 M |
| dbacp00187 | Citropin modified peptide-16 | GLFAVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Skin tumor cell line | Skin cancer | IC50 : 5 M |
| dbacp00188 | Citropin modified peptide-16 | GLFAVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00189 | Citropin modified peptide-16 | GLFAVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : 5 M |
| dbacp00190 | Citropin modified peptide-16 | GLFAVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00191 | Citropin modified peptide-16 | GLFAVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00217 | Citropin modified peptide-17 | GLFAVIKKVAAVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00218 | Citropin modified peptide-17 | GLFAVIKKVAAVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00219 | Citropin modified peptide-17 | GLFAVIKKVAAVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Colon tumor cell line | Colon cancer | IC50 : 5 M |
| dbacp00220 | Citropin modified peptide-17 | GLFAVIKKVAAVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Brain tumor cell line | Brain tumor | IC50 : 5 M |
| dbacp00221 | Citropin modified peptide-17 | GLFAVIKKVAAVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Skin tumor cell line | Skin cancer | IC50 : 5 M |
| dbacp00222 | Citropin modified peptide-17 | GLFAVIKKVAAVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00223 | Citropin modified peptide-17 | GLFAVIKKVAAVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : 5 M |
| dbacp00224 | Citropin modified peptide-17 | GLFAVIKKVAAVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00225 | Citropin modified peptide-17 | GLFAVIKKVAAVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00252 | Citropin modified peptide-18 | GLFAVIKKVAAVIRRL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00253 | Citropin modified peptide-18 | GLFAVIKKVAAVIRRL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00254 | Citropin modified peptide-18 | GLFAVIKKVAAVIRRL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Colon tumor cell line | Colon cancer | IC50 : 5 M |
| dbacp00255 | Citropin modified peptide-18 | GLFAVIKKVAAVIRRL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Brain tumor cell line | Brain tumor | IC50 : 5 M |
| dbacp00256 | Citropin modified peptide-18 | GLFAVIKKVAAVIRRL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Skin tumor cell line | Skin cancer | IC50 : 5 M |
| dbacp00257 | Citropin modified peptide-18 | GLFAVIKKVAAVIRRL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00258 | Citropin modified peptide-18 | GLFAVIKKVAAVIRRL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : >10 µM |
| dbacp00259 | Citropin modified peptide-18 | GLFAVIKKVAAVIRRL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00260 | Citropin modified peptide-18 | GLFAVIKKVAAVIRRL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00261 | Citropin modified peptide-19 | GLFAVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00262 | Citropin modified peptide-19 | GLFAVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 6 M |
| dbacp00263 | Citropin modified peptide-19 | GLFAVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Colon tumor cell line | Colon cancer | IC50 : 5 M |
| dbacp00264 | Citropin modified peptide-19 | GLFAVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Brain tumor cell line | Brain tumor | IC50 : 5 M |
| dbacp00265 | Citropin modified peptide-19 | GLFAVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Skin tumor cell line | Skin cancer | IC50 : 5 M |
| dbacp00266 | Citropin modified peptide-19 | GLFAVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00267 | Citropin modified peptide-19 | GLFAVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : 5 M |
| dbacp00268 | Citropin modified peptide-19 | GLFAVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00269 | Citropin modified peptide-19 | GLFAVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00270 | Citropin modified peptide-22 | GLFKVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00271 | Citropin modified peptide-22 | GLFKVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00272 | Citropin modified peptide-22 | GLFKVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Colon tumor cell line | Colon cancer | IC50 : 5 M |
| dbacp00273 | Citropin modified peptide-22 | GLFKVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Brain tumor cell line | Brain tumor | IC50 : 5 M |
| dbacp00274 | Citropin modified peptide-22 | GLFKVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Skin tumor cell line | Skin cancer | IC50 : 5 M |
| dbacp00275 | Citropin modified peptide-22 | GLFKVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00276 | Citropin modified peptide-22 | GLFKVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : >10 µM |
| dbacp00277 | Citropin modified peptide-22 | GLFKVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : >10 µM |
| dbacp00278 | Citropin modified peptide-22 | GLFKVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp00292 | Citropin modified peptide-23 | GLFKVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00293 | Citropin modified peptide-23 | GLFKVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp00294 | Citropin modified peptide-23 | GLFKVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Colon tumor cell line | Colon cancer | IC50 : 5 M |
| dbacp00295 | Citropin modified peptide-23 | GLFKVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Brain tumor cell line | Brain tumor | IC50 : 5 M |
| dbacp00296 | Citropin modified peptide-23 | GLFKVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Skin tumor cell line | Skin cancer | IC50 : 5 M |
| dbacp00297 | Citropin modified peptide-23 | GLFKVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp00298 | Citropin modified peptide-23 | GLFKVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : >10 µM |
| dbacp00299 | Citropin modified peptide-23 | GLFKVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp00300 | Citropin modified peptide-23 | GLFKVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp02488 | Citropin 1.1 | GLFDVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp02489 | Citropin 1.1 | GLFDVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp02490 | Citropin 1.1 | GLFDVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Colon tumor cell line | Colon cancer | IC50 : 5 M |
| dbacp02491 | Citropin 1.1 | GLFDVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Brain tumor cell line | Brain tumor | IC50 : 5 M |
| dbacp02492 | Citropin 1.1 | GLFDVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Skin tumor cell line | Skin cancer | IC50 : 5 M |
| dbacp02493 | Citropin 1.1 | GLFDVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp02494 | Citropin 1.1 | GLFDVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : 5 M |
| dbacp02495 | Citropin 1.1 | GLFDVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp02496 | Citropin 1.1 | GLFDVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp02498 | Citropin 1.1 | GLFDVIKKVASVIGGL | Blue mountains tree frog | Penetration and disruption of the membranes | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : 5 M |
| dbacp02499 | Citropin 1.1D | glfdvikkvasviggl | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp02500 | Citropin 1.1D | glfdvikkvasviggl | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp02501 | Citropin 1.1D | glfdvikkvasviggl | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Colon tumor cell line | Colon cancer | IC50 : 5 M |
| dbacp02502 | Citropin 1.1D | glfdvikkvasviggl | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Brain tumor cell line | Brain tumor | IC50 : 5 M |
| dbacp02503 | Citropin 1.1D | glfdvikkvasviggl | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Skin tumor cell line | Skin cancer | IC50 : 5 M |
| dbacp02504 | Citropin 1.1D | glfdvikkvasviggl | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp02505 | Citropin 1.1D | glfdvikkvasviggl | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : 5 M |
| dbacp02506 | Citropin 1.1D | glfdvikkvasviggl | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : 5 M |
| dbacp02507 | Citropin 1.1D | glfdvikkvasviggl | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : 5 M |
| dbacp03644 | Lan-7 | fA*YwKA*T | Analogue of TT-232 | Tubulin depolymerization | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 17.05 ± 6.61 µM |
| dbacp03645 | Lan-7 | fA*YwKA*T | Analogue of TT-232 | Tubulin depolymerization | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 16.93 ± 1.84 µM |
| dbacp03646 | Lan-7 | fA*YwKA*T | Analogue of TT-232 | Tubulin depolymerization | Sulforhodamine B assay | UMSCC10b | Head and neck cancer | IC50 : 33.88 ± 1.98 µM |
| dbacp03647 | Lan-7 | fA*YwKA*T | Analogue of TT-232 | Tubulin depolymerization | Sulforhodamine B assay | UMSCC10b | Head and neck cancer | IC50 : 27.69 ± 2.17 µM |
| dbacp03648 | Lan-7 | fA*YwKA*T | Analogue of TT-232 | Tubulin depolymerization | Sulforhodamine B assay | HCT-116 | Colon cancer | IC50 : 29.97 ± 1.19 µM |
| dbacp03649 | Lan-7 | fA*YwKA*T | Analogue of TT-232 | Tubulin depolymerization | Sulforhodamine B assay | HEC-59 | Endometrial cancer | IC50 : 36.81 ± 0.40 µM |
| dbacp05934 | Retro | LGGIVSAVKKIVDFLG | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp05935 | Retro | LGGIVSAVKKIVDFLG | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Lung tumor cell line | Lung cancer | IC50 : 5 M |
| dbacp05936 | Retro | LGGIVSAVKKIVDFLG | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Colon tumor cell line | Colon cancer | IC50 : >10 µM |
| dbacp05937 | Retro | LGGIVSAVKKIVDFLG | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Brain tumor cell line | Brain tumor | IC50 : 5 M |
| dbacp05938 | Retro | LGGIVSAVKKIVDFLG | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Skin tumor cell line | Skin cancer | IC50 : 5 M |
| dbacp05939 | Retro | LGGIVSAVKKIVDFLG | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Ovary tumor cell line | Ovarian cancer | IC50 : 5 M |
| dbacp05940 | Retro | LGGIVSAVKKIVDFLG | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Liver tumor celline | Liver cancer | IC50 : >10 µM |
| dbacp05941 | Retro | LGGIVSAVKKIVDFLG | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Prostate tumor cell line | Prostate cancer | IC50 : >10 µM |
| dbacp05942 | Retro | LGGIVSAVKKIVDFLG | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Breast tumor cell line | Breast cancer | IC50 : >10 µM |
| dbacp07244 | CIGB-552 | HARIKpTFRRlKWKYKGKFW | Synthetic | NF-κB inhibition enhances cisplatin synergy | Sulforhodamine B assay | NCI-H-460 | Lung Cancer | IC50 = 287.9 μM |
| dbacp07245 | CIGB-552 | HARIKpTFRRlKWKYKGKFW | Synthetic | NF-κB inhibition enhances cisplatin synergy | Sulforhodamine B assay | A-549 | Lung Cancer | IC50 = 44.6 μM |
| dbacp07287 | P264-G274 | PARDVLNTTSG | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-480 | Colorectal Cancer | EC50 = 90.98 ± 0.75 µM |
| dbacp07288 | P264-G274 | PARDVLNTTSG | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-620 | Colorectal Cancer | EC50 = 11.28 ± 0.52 µM |
| dbacp07289 | Loop1-PS2Aa | NNETYFNAVKP | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-480 | Colorectal Cancer | EC50 = 23.76 ± 1.25 µM |
| dbacp07290 | Loop1-PS2Aa | NNETYFNAVKP | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-620 | Colorectal Cancer | EC50 = 106.2 ± 1.67 µM |
| dbacp07291 | Loop2-PS2Aa | TYFNAVKPPITA | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-480 | Colorectal Cancer | EC50 = 92.99 ± 0.98 µM |
| dbacp07292 | Loop2-PS2Aa | TYFNAVKPPITA | Parasporin-2Aa1 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-620 | Colorectal Cancer | EC50 = 15.95 ± 0.69 µM |
| dbacp07293 | Loop1-HCoV-229E | FKPQSGGGKCF | Alphacoronavirus (HCoV-229E) | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-480 | Colorectal Cancer | EC50 = 125.0 ± 1.32 µM |
| dbacp07294 | A4W-GGN5 | FLGWLFKVASK | Gaegurin 5 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-480 | Colorectal Cancer | EC50 = 98.63 ± 1.17 µM |
| dbacp07295 | A4W-GGN5 | FLGWLFKVASK | Gaegurin 5 | h-APN receptor–mediated apoptosis induction. | Sulforhodamine B assay | SW-620 | Colorectal Cancer | EC50 = 22.07 ± 1.63 µM |
| dbacp08150 | CIGB-552 | HARIKpTFRRlKWKYKGKFW | Synthetic | Not Available | Sulforhodamine B assay | MCF-7 | Breast Cancer | IC50 = 379.1 ± 8.6 µM |